Traders should monitor the resumption of India biodiesel tenders and progress on the MVR upgrade as key catalysts. Near-term sentiment may improve due to Q4 cost reductions and biogas strength, but structural recovery depends on execution in India and realization of efficiency gains in 2026.
How the stock moved after the report
NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · Mar 12 $1.92entry
- T+1 · 8mo ago +19.27%α +19.87% · $2.29
- T+5 · 8mo ago +37.50%α +38.48% · $2.64
- T+20 · 7mo ago +18.23%α +16.25% · $2.27
- T+60 · 5mo ago +17.19%α +6.49% · $2.25
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Aemetis reported Q4 and full-year 2025 results with improved quarterly performance driven by strong biogas growth and lower costs, but full-year revenue declined significantly due to setbacks in India and lower ethanol output. Dairy RNG production surged 61% YoY in Q4, and the company expects $32M in annual cash flow uplift from an ethanol plant upgrade. However, full-year 2025 revenue fell to $197.6M from $267.6M in 2024, primarily due to a $63M drop in India biodiesel sales.
Key Financial Metrics
Key Facts
- Q4 2025 revenues and tax credits: $53.7M vs. $47.0M in Q4 2024 (+14.3%)
- Full-year 2025 revenue: $197.6M vs. $267.6M in 2024 (-26.1%)
- India biodiesel revenue dropped $63.2M due to structural program challenges
- Dairy RNG production up 61% YoY in Q4; Biogas segment net income reached $12.2M in Q4
- Ethanol plant MVR upgrade expected to boost annual cash flow by $32M starting in 2026
- Net loss narrowed to $77.0M in 2025 from $87.5M in 2024
Financial Impact
Revenue down $70M YoY, but path to future cash flow improvement with $32M annual benefit from MVR project and resumption of India sales at year-end
Risk Factors
- Continued volatility in India's biodiesel policy and tender delays
- Execution risk on MVR project and timeline slippage beyond 2026
- High leverage with $279M current portion of long-term debt vs. $4.9M cash
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3254548 |
Track record
7 reports on AMTX
The track record builds as more bullish or bearish reports settle.
Filters
- Nov 5, 202611d ago 8-K Bullish 6/10 No price data
- Nov 5, 202611d ago Press Release Neutral 4/10 Entry $1.73 Now $1.20 −30.64% settles Feb 3
- Sep 22, 20267w ago Institutional Cluster Mixed 3/10 Entry $2.12 Now $1.20 −43.26% settles Dec 16
- Aug 6, 202614w ago Press Release Bearish 7/10 Entry $1.63 to $1.25 Now $1.20 +26.38% ▲ +23.31% +21.64% vs SPY
- May 7, 202627w ago 8-K Bearish 7/10 Entry $3.12 to $1.52 Now $1.20 +61.54% ▲ +51.28% +55.12% vs SPY
- May 1, 202628w ago Press Release Neutral 1/10 Entry $3.52 to $1.48 Now $1.20 −65.91% ▼ −57.95% −61.02% vs SPY
- Mar 12, 202635w ago Press Release Mixed 6/10 Viewing Entry $1.92 to $2.25 Now $1.20 −37.50% ▲ +17.19% +6.49% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers